Yuka Kasamatsu

Yuka Kasamatsu

Auto-generated profile, based on publicly available information

Yuka Kasamatsu

Shizuoka Cancer Center, Suntogun, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AOAna Oaknin
Ana Oaknin
SGSharad A. Ghamande
Sharad A. Ghamande
YKYuka Kasamatsu
Yuka Kasamatsu
MMMarta Gil Martin
Marta Gil Martin
JBJuan Francisco Grau Bejar
Juan Francisco Grau Bejar
KHKosei Hasegawa
Kosei Hasegawa
Purpose: Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGFβ receptor II (a TGFβ “trap”) fused to a human IgG1 mAb blocking programmed death-ligand 1 (PD-L1), was evaluated as treatment in patients with locally advanced or persistent, recurrent, or metastatic (P/R/M) cervical cancer. Patients and Methods: In this multicenter, open-label, phase Ib trial (NCT04551950), patients with P/R/M cervical cancer received bintrafusp alfa 2,400 mg once every 3 weeks plus cisplatin or carboplatin plus paclitaxel with (Cohort 1A; n = 8) or without (Cohort 1B; n = 9) bevacizumab; patients with locally advanced cervical cancer received bintrafusp alfa 2,400 mg every 3 weeks plus cisplatin plus radiation, followed by bintrafusp alfa monotherapy maintenance (Cohort 2; n = 8). The primary endpoint was safety; secondary endpoints included efficacy (including objective response rate) and pharmacokinetics. Results: At the data cutoff of April 27, 2022, patients in Cohorts 1A, 1B, and 2 had received bintrafusp alfa for a median duration of 37.9, 31.1, and 16.7 weeks, respectively. Two dose-limiting toxicities (grade 4 amylase elevation and grade 3 menorrhagia) unrelated to bintrafusp alfa were observed in Cohort 1B and none in other cohorts. Most treatment-emergent adverse events of special interest were grades 1–2 in severity, most commonly anemia (62.5%–77.8%) and bleeding events (62.5%–77.8%). Objective response rate was 75.0% [95% confidence interval (CI), 34.9–96.8], 44.4% (95% CI, 13.7–78.8), and 62.5% (95% CI, 24.5–91.5) in Cohorts 1A, 1B, and 2, respectively. Conclusions: Bintrafusp alfa had manageable safety and demonstrated clinical activity, further supporting the investigation of TGFβ/PD-L1 inhibition in human papillomavirus–associated cancers, including cervical cancer.

1 January 2021 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
KHKensuke Hori
Kensuke Hori
Shin NishioShin Nishio
Shin Nishio
KUKimio Ushijima
Kimio Ushijima
YKYuka Kasamatsu
Yuka Kasamatsu
Eiji KondoEiji Kondo
Eiji Kondo
KIKimihiko Ito
Kimihiko Ito
Hori K, et al. J Gynecol Oncol. 2021 May;32:e64. https://doi.org/10.3802/jgo.2021.32.e64

1 March 2024
Verified
Other
Open access
AOAna Oaknin
Ana Oaknin
SGSharad A. Ghamande
Sharad A. Ghamande
YKYuka Kasamatsu
Yuka Kasamatsu
MMMarta Gil Martin
Marta Gil Martin
JBJuan Francisco Grau Bejar
Juan Francisco Grau Bejar
KHKosei Hasegawa
Kosei Hasegawa
Figure S2. Change from baseline in sum of diameters of all target lesions per RECIST v1.1 for Cohort 2. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.


1 March 2024
Verified
Other
Open access
AOAna Oaknin
Ana Oaknin
SGSharad A. Ghamande
Sharad A. Ghamande
YKYuka Kasamatsu
Yuka Kasamatsu
MMMarta Gil Martin
Marta Gil Martin
JBJuan Francisco Grau Bejar
Juan Francisco Grau Bejar
KHKosei Hasegawa
Kosei Hasegawa
Table S4. Pharmacokinetic exposure summary. AUC, area under the curve; Ceoi, concentration at end of infusion; Ctrough, concentration at the end of the dosing interval; CV, coefficient of variation; NA, not applicable; popPK, population pharmacokinetic; SD, standard deviation.

1 March 2024
Verified
Other
Open access
AOAna Oaknin
Ana Oaknin
SGSharad A. Ghamande
Sharad A. Ghamande
YKYuka Kasamatsu
Yuka Kasamatsu
MMMarta Gil Martin
Marta Gil Martin
JBJuan Francisco Grau Bejar
Juan Francisco Grau Bejar
KHKosei Hasegawa
Kosei Hasegawa
Table S1. Median duration of therapy. IQR, interquartile range; NA, not applicable.